Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 59.9 kDa. The protein migrates as >85 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus Flt-3 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Cynomolgus Flt-3 Protein, His Tag (Cat. No. FL3-C52H5) is more than 90% and the molecular weight of this protein is around 75-95 kDa verified by SEC-MALS.
Immobilized Cynomolgus Flt-3 Protein, His Tag (Cat. No. FL3-C52H5) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Flt-3 Ligand, His,Avitag (Cat. No. FLL-H82E6) with a linear range of 0.1-2 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Quizartinib | AC-010220; ASP-2689; AC-220 | Approved | Ambit Biosciences Co | Vanflyta | Japan | Leukemia, Myeloid, Acute | Daiichi Sankyo Co Ltd | 2019-06-18 | Leukemia; Leukemia, Myeloid; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute | Details |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals U.S.A. Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Small Cell Lung Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Brain metastases; Lung Neoplasms; Granuloma, Plasma Cell; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Meningioma; Neuroma, Acoustic | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Adenocarcinoma, Clear Cell; systemic sclerosis-associated interstitial lung disease; Colorectal Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Hepatic Insufficiency; Astrocytoma; Genital Neoplasms, Female; Silicosis; Sarcoma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Appendiceal Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Endometrioid; Scleroderma, Systemic; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Rejection of lung transplantation; Carcinoma, Renal Cell; Radiation Pneumonitis; Esophageal Neoplasms; Carcinoid Tumor; Endometrial Stromal Tumors; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Glioblastoma; Colonic Neoplasms; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Oligodendroglioma; Multiple Myeloma; Mesothelioma; Asbestosis; Neuroendocrine Tumors | Details |
Vorolanib | X-82; EYP-1901; CM-082 | Approved | Tyrogenex Inc | 伏美纳 | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Diabetic macular oedema; Carcinoma, Non-Small-Cell Lung; Melanoma; Macular Degeneration; Carcinoma, Hepatocellular; Diabetic Retinopathy; Choroidal Neovascularization; Adenocarcinoma; Retinal Degeneration; Leukemia, Myeloid, Acute; Eye Diseases; Solid tumours; Wet Macular Degeneration; Retinal Diseases; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms | Details |
Gilteritinib Fumarate | ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) | Approved | Astellas Pharma Inc | Xospata | Japan | Leukemia, Myeloid, Acute | Astellas Pharma Inc | 2018-09-21 | Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
pacritinib citrate | SB-1518; ONX-0803 | Approved | S*BIO Pte Ltd, Concert | VONJO | United States | Primary Myelofibrosis | Cti Biopharma Corp | 2022-02-28 | Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocythemia, Essential; Sarcoma, Kaposi; Thrombocytopenia; Lymphoma, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myelomonocytic, Juvenile; Lymphoma, T-Cell, Cutaneous; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Colorectal Neoplasms; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Lymphoma, T-Cell, Peripheral; Castleman Disease; Primary Myelofibrosis; Coronavirus Infections; Lymphoma, Mantle-Cell; Coronavirus Disease 2019 (COVID-19); Hodgkin Disease; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Myelodysplastic Syndromes; Polycythemia Vera; Lymphoma, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia | Details |
Fedratinib | TG-101348; SAR-302503 | Approved | Sanofi | Inrebic | United States | Primary Myelofibrosis | Bristol-Myers Squibb Company | 2019-08-16 | Hematologic Neoplasms; Solid tumours; Polycythemia Vera; Kidney Diseases; Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Neutrophilic, Chronic; Primary Myelofibrosis; Hepatic Insufficiency; Splenomegaly; Thrombocythemia, Essential | Details |
Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | Iclusig | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Ariad Pharmaceuticals Inc | 2012-12-14 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Common Bile Duct Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Medullary thyroid cancer (MTC); Leukemia, Myelogenous, Chronic; Blast Crisis; Glioblastoma; Leukemia, Myelomonocytic, Chronic; Adenocarcinoma of Lung; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia; Head and Neck Neoplasms | Details |
Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; GB-102; PNU-290940; SU-011248-L-malate salt; PHA-290940; SU-010398; SU-11248 | Approved | Pfizer Inc | 索坦, Sutent | United States | Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors | Cppi Cv | 2006-01-26 | Solid tumours; Fibromatosis, Aggressive; Ovarian Neoplasms; Kidney Neoplasms; Leukemia, Myelogenous, Chronic; Head and Neck Neoplasms; Leiomyosarcoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; HIV Infections; Leukemia, Myeloid, Accelerated Phase; Leukemia; Fibrosarcoma; Teratoma; Liver Neoplasms; Ependymoma; Lymphoma, T-Cell, Peripheral; Intestinal Neoplasms; Histiocytoma, Malignant Fibrous; Carcinoma, Renal Cell; Hemangioblastoma; Carcinoma, Islet Cell; Carcinoma; Pheochromocytoma; Stomach Neoplasms; Pelvic Neoplasms; Esophageal Neoplasms; Leukemia, Hairy Cell; Polycythemia Vera; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Carcinoma, Ovarian Epithelial; Glioblastoma; Neurofibromatoses; Small Cell Lung Carcinoma; Adenoma, Islet Cell; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Myelodysplastic Syndromes; Hodgkin Disease; Leukemia, Myelomonocytic, Chronic; Carcinoma, Papil | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Neurofibrosarcoma; Giant Cell Tumors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neurofibroma, Plexiform; Sarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours; Breast Neoplasms; Neoplasms; Arthritis, Rheumatoid; Hodgkin Disease; Glioblastoma; Pancreatic Neoplasms; Synovitis, Pigmented Villonodular; Squamous Cell Carcinoma of Head and Neck; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Giant Cell Tumor of Tendon Sheath | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Exelixis Inc | 2012-11-29 | Urethral Neoplasms; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Peritoneal Neoplasms; Bile Duct Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Adenocarcinoma, Clear Cell; Sarcoma, Ewing; Carcinoma, Adenosquamous; Breast Neoplasms; Neurofibroma, Plexiform; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Medullary thyroid cancer (MTC); Carcinoma, Hepatocellular; Melanoma; Paraganglioma; Meningioma; Neoplasms, Germ Cell and Embryonal; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Brain Neoplasms; Carcinoma, Neuroendocrine; Sarcoma, Alveolar Soft Part; Lymphoma; Fallopian Tube Neoplasms; Brain metastases; Glioma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoid Tumor; Glioblastoma; Skin Neoplasms; Neoplasms; Carcinoma, Papillary; Hepatoblastoma; Pheochromocytoma; Pain; Rejection of liver transplantation; Carcinoma, Renal Cell; Pancreatic neuroendocrine tumors | Details |
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Kidney Neoplasms; Recurrence; Ovarian Neoplasms; Leukemia, Myelogenous, Chronic; Lymphoma, T-Cell, Peripheral; Leukemia, Erythroblastic, Acute; Rhabdomyosarcoma; Lymphoma, B-Cell, Marginal Zone; Fibromatosis, Aggressive; Head and Neck Neoplasms; Solid tumours; Leiomyosarcoma; Leukemia, Myeloid; Carcinoma, Renal Cell; Carcinoma; Vipoma; Esophageal Neoplasms; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Carcinoid Tumor; Histiocytoma, Malignant Fibrous; Carcinoma, Islet Cell; Insulinoma; Stomach Neoplasms; Neoplasms; Kidney Diseases; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Thyroid Carcinoma, Anaplastic; Myelodysplastic Syndromes; Glioblastoma; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Wilms Tumor; Lymphomatoid Granulomatosis; Colonic Neoplasms; Hypertension, Portal; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Multiple Endo | Details |
Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Mastocytosis, Systemic; Leukemia, Mast-Cell; Hematologic Neoplasms; Leukemia, Myeloid, Acute | Novartis Pharmaceuticals Corp | 2017-04-28 | Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
Quizartinib | AC-010220; ASP-2689; AC-220 | Approved | Ambit Biosciences Co | Vanflyta | Japan | Leukemia, Myeloid, Acute | Daiichi Sankyo Co Ltd | 2019-06-18 | Leukemia; Leukemia, Myeloid; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute | Details |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals U.S.A. Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Small Cell Lung Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Brain metastases; Lung Neoplasms; Granuloma, Plasma Cell; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Meningioma; Neuroma, Acoustic | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Adenocarcinoma, Clear Cell; systemic sclerosis-associated interstitial lung disease; Colorectal Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Hepatic Insufficiency; Astrocytoma; Genital Neoplasms, Female; Silicosis; Sarcoma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Appendiceal Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Endometrioid; Scleroderma, Systemic; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Rejection of lung transplantation; Carcinoma, Renal Cell; Radiation Pneumonitis; Esophageal Neoplasms; Carcinoid Tumor; Endometrial Stromal Tumors; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Glioblastoma; Colonic Neoplasms; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Oligodendroglioma; Multiple Myeloma; Mesothelioma; Asbestosis; Neuroendocrine Tumors | Details |
Vorolanib | X-82; EYP-1901; CM-082 | Approved | Tyrogenex Inc | 伏美纳 | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Diabetic macular oedema; Carcinoma, Non-Small-Cell Lung; Melanoma; Macular Degeneration; Carcinoma, Hepatocellular; Diabetic Retinopathy; Choroidal Neovascularization; Adenocarcinoma; Retinal Degeneration; Leukemia, Myeloid, Acute; Eye Diseases; Solid tumours; Wet Macular Degeneration; Retinal Diseases; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms | Details |
Gilteritinib Fumarate | ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) | Approved | Astellas Pharma Inc | Xospata | Japan | Leukemia, Myeloid, Acute | Astellas Pharma Inc | 2018-09-21 | Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
pacritinib citrate | SB-1518; ONX-0803 | Approved | S*BIO Pte Ltd, Concert | VONJO | United States | Primary Myelofibrosis | Cti Biopharma Corp | 2022-02-28 | Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocythemia, Essential; Sarcoma, Kaposi; Thrombocytopenia; Lymphoma, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myelomonocytic, Juvenile; Lymphoma, T-Cell, Cutaneous; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Colorectal Neoplasms; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Lymphoma, T-Cell, Peripheral; Castleman Disease; Primary Myelofibrosis; Coronavirus Infections; Lymphoma, Mantle-Cell; Coronavirus Disease 2019 (COVID-19); Hodgkin Disease; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Myelodysplastic Syndromes; Polycythemia Vera; Lymphoma, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia | Details |
Fedratinib | TG-101348; SAR-302503 | Approved | Sanofi | Inrebic | United States | Primary Myelofibrosis | Bristol-Myers Squibb Company | 2019-08-16 | Hematologic Neoplasms; Solid tumours; Polycythemia Vera; Kidney Diseases; Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Neutrophilic, Chronic; Primary Myelofibrosis; Hepatic Insufficiency; Splenomegaly; Thrombocythemia, Essential | Details |
Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | Iclusig | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Ariad Pharmaceuticals Inc | 2012-12-14 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Common Bile Duct Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Medullary thyroid cancer (MTC); Leukemia, Myelogenous, Chronic; Blast Crisis; Glioblastoma; Leukemia, Myelomonocytic, Chronic; Adenocarcinoma of Lung; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia; Head and Neck Neoplasms | Details |
Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; GB-102; PNU-290940; SU-011248-L-malate salt; PHA-290940; SU-010398; SU-11248 | Approved | Pfizer Inc | 索坦, Sutent | United States | Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors | Cppi Cv | 2006-01-26 | Solid tumours; Fibromatosis, Aggressive; Ovarian Neoplasms; Kidney Neoplasms; Leukemia, Myelogenous, Chronic; Head and Neck Neoplasms; Leiomyosarcoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; HIV Infections; Leukemia, Myeloid, Accelerated Phase; Leukemia; Fibrosarcoma; Teratoma; Liver Neoplasms; Ependymoma; Lymphoma, T-Cell, Peripheral; Intestinal Neoplasms; Histiocytoma, Malignant Fibrous; Carcinoma, Renal Cell; Hemangioblastoma; Carcinoma, Islet Cell; Carcinoma; Pheochromocytoma; Stomach Neoplasms; Pelvic Neoplasms; Esophageal Neoplasms; Leukemia, Hairy Cell; Polycythemia Vera; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Carcinoma, Ovarian Epithelial; Glioblastoma; Neurofibromatoses; Small Cell Lung Carcinoma; Adenoma, Islet Cell; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Myelodysplastic Syndromes; Hodgkin Disease; Leukemia, Myelomonocytic, Chronic; Carcinoma, Papil | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Neurofibrosarcoma; Giant Cell Tumors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neurofibroma, Plexiform; Sarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours; Breast Neoplasms; Neoplasms; Arthritis, Rheumatoid; Hodgkin Disease; Glioblastoma; Pancreatic Neoplasms; Synovitis, Pigmented Villonodular; Squamous Cell Carcinoma of Head and Neck; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Giant Cell Tumor of Tendon Sheath | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Exelixis Inc | 2012-11-29 | Urethral Neoplasms; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Peritoneal Neoplasms; Bile Duct Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Adenocarcinoma, Clear Cell; Sarcoma, Ewing; Carcinoma, Adenosquamous; Breast Neoplasms; Neurofibroma, Plexiform; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Medullary thyroid cancer (MTC); Carcinoma, Hepatocellular; Melanoma; Paraganglioma; Meningioma; Neoplasms, Germ Cell and Embryonal; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Brain Neoplasms; Carcinoma, Neuroendocrine; Sarcoma, Alveolar Soft Part; Lymphoma; Fallopian Tube Neoplasms; Brain metastases; Glioma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoid Tumor; Glioblastoma; Skin Neoplasms; Neoplasms; Carcinoma, Papillary; Hepatoblastoma; Pheochromocytoma; Pain; Rejection of liver transplantation; Carcinoma, Renal Cell; Pancreatic neuroendocrine tumors | Details |
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Kidney Neoplasms; Recurrence; Ovarian Neoplasms; Leukemia, Myelogenous, Chronic; Lymphoma, T-Cell, Peripheral; Leukemia, Erythroblastic, Acute; Rhabdomyosarcoma; Lymphoma, B-Cell, Marginal Zone; Fibromatosis, Aggressive; Head and Neck Neoplasms; Solid tumours; Leiomyosarcoma; Leukemia, Myeloid; Carcinoma, Renal Cell; Carcinoma; Vipoma; Esophageal Neoplasms; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Carcinoid Tumor; Histiocytoma, Malignant Fibrous; Carcinoma, Islet Cell; Insulinoma; Stomach Neoplasms; Neoplasms; Kidney Diseases; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Thyroid Carcinoma, Anaplastic; Myelodysplastic Syndromes; Glioblastoma; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Wilms Tumor; Lymphomatoid Granulomatosis; Colonic Neoplasms; Hypertension, Portal; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Multiple Endo | Details |
Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Mastocytosis, Systemic; Leukemia, Mast-Cell; Hematologic Neoplasms; Leukemia, Myeloid, Acute | Novartis Pharmaceuticals Corp | 2017-04-28 | Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
XY-0206 | XY-0206 | Phase 3 Clinical | Nanjing University Of Chinese Medicine | Solid tumours; Leukemia, Myeloid, Acute | Details |
Clifutinib Besylate | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details | |
KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis | Details |
SKLB-1028 | SKLB-1028 | Phase 3 Clinical | Sichuan University, CSPC Pharmaceutical Group Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neuroblastoma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
HEC-73543 | HEC-73543 | Phase 3 Clinical | Hec Pharm Co Ltd | Leukemia, Myeloid, Acute | Details |
Crenolanib Besylate | CP-868596-26; IND-112201; CP-868596; ARO-002; ARO-002-26 | Phase 3 Clinical | Pfizer Inc | Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Glioma | Details |
HYML-122 | HYML-122; CHMFL-FLT3-122 | Phase 2 Clinical | Hefei Academy Of Physical Sciences, Chinese Academy Of Sciences, Hefei Cosource Pharmaceuticals | Leukemia, Myeloid, Acute | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
MRX-2843 | UNC-2371; UNC-2025; MRX-2843 | Phase 2 Clinical | University Of North Carolina At Chapel Hill | Leukemia; Solid tumours; Neoplasms; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lung Neoplasms; Leukemia, Myeloid, Acute; Neoplastic Processes; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Emavusertib | AU-4948; CA-4948 | Phase 2 Clinical | Aurigene | Anemia; Stomach Neoplasms; Esophageal Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Digestive System Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Pancreatic Ductal; Lymphoma, Non-Hodgkin; Gastrointestinal Neoplasms; Melanoma | Details |
Zotiraciclib | TG-02; SB-1317 | Phase 2 Clinical | Syncore Biotechnology Co Ltd | Glioblastoma; Neoplasms; Brain Neoplasms; Astrocytoma; Gliosarcoma; Glioma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular | Details |
NMS-03592088 | NMS-P088; NMS-03592088 | Phase 2 Clinical | Nerviano Medical Sciences Srl | Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
MAX-40279 | MAX-40279-001; Max-40279; MAX-40279-01; MAX-4 | Phase 2 Clinical | Maxinovel Pharmaceuticals Co Ltd | Solid tumours; Leukemia; Esophageal Neoplasms; Stomach Neoplasms; Idiopathic Pulmonary Fibrosis; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis | Details |
Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Fms-like tyrosine kinase 3 ligand (Celldex Therapeutics) | CDX-301 | Phase 2 Clinical | Amgen Inc | Sarcoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Osteosarcoma; Skin Melanoma; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Myelodysplastic Syndromes; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Leukemia, Myelogenous, Chronic | Details |
Tuspetinib | HM-43239 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
Flysyn | 4G8-SDIEM | Phase 2 Clinical | Synimmune Gmbh | Leukemia, Myeloid, Acute | Details |
Glesatinib | MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 | Phase 2 Clinical | Mirati Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
FF-10101 | FF-10101; FF-10101-01; FF-10101 succinate | Phase 2 Clinical | Fujifilm Corp | Leukemia, Myeloid, Acute | Details |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
Anti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine) | TAA05 | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
Flonoltinib maleate | Phase 2 Clinical | Chengdu Zenitar Biomedical Technology Co Ltd | Polycythemia Vera; Alopecia Areata; Myeloproliferative Disorders; Primary Myelofibrosis; Lymphohistiocytosis, Hemophagocytic; Thrombocythemia, Essential | Details | |
EP-0042 | EP-0042 | Phase 2 Clinical | Ellipses Pharma | Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
MEN-1703 | SEL-24-1; MEN-1703; SEL24/MEN1703; SEL24; SEL-24; SEL-24-B489 | Phase 2 Clinical | Ryvu Therapeutics Sa | Leukemia, Myeloid, Acute | Details |
FN-1501 | FN-1501; LT-171-861 | Phase 2 Clinical | China Pharmaceutical University, Shanghai Fosun Pharmaceutical Industrial Development Co Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular | Details |
Mivavotinib | TAK-659; CB-659 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd | Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
E-6201 | E-6201 | Phase 1 Clinical | Eisai Co Ltd | Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Psoriasis; Brain metastases; Leukemia, Myeloid, Acute; Melanoma | Details |
SENTI-202 | SENTI-202 | Phase 1 Clinical | Senti Biosciences Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
ETH-155008 | ETH-155008 | Phase 1 Clinical | Yunnan Shengke Pharmaceutical Co Ltd | Leukemia; Leukemia, Promyelocytic, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute | Details |
CLN-049 | CLN-049 | Phase 1 Clinical | University Of Tubingen, German Cancer Research Center (Dkfz) | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
Lomonitinib | Phase 1 Clinical | Eilean Therapeutics LLC | Details | ||
KME-0584 | KME-0584 | Phase 1 Clinical | National Center For Advancing Translational Sciences, Cincinnati Children'S Hospital Medical Center | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Lomonitinib | ZE46-0134; ZE-46-0134; ZE-460134 | Phase 1 Clinical | Eilean Therapeutics LLC | Leukemia, Promyelocytic, Acute; Leukemia, Myeloid, Acute | Details |
ETH-155036 | ETH-155036; ETH155036 | Phase 1 Clinical | Shengke Pharmaceutical (Jiangsu) Co Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
BMF-500 | BMF-500 | Phase 1 Clinical | Biomea Fusion Inc | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
PHI-101 | PHI-101; PHI-101-002; PHI-101-003 | Phase 1 Clinical | Pharos iBio Co Ltd | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute | Details |
LNK-01002 | LNK01002 | Phase 1 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Hematologic Neoplasms; Polycythemia Vera; Myeloproliferative Disorders; Primary Myelofibrosis; Leukemia, Myeloid, Acute | Details |
SKI-G-801 | G-801; SKI-G-801; G-749 Hydrochloride | Phase 1 Clinical | Oscotec Inc | Solid tumours; Leukemia, Myeloid, Acute | Details |
Luxeptinib | CG-806; CG-026806 | Phase 1 Clinical | Crystalgenomics Inc, Aptose | Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
XY-0206 | XY-0206 | Phase 3 Clinical | Nanjing University Of Chinese Medicine | Solid tumours; Leukemia, Myeloid, Acute | Details |
Clifutinib Besylate | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details | |
KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis | Details |
SKLB-1028 | SKLB-1028 | Phase 3 Clinical | Sichuan University, CSPC Pharmaceutical Group Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neuroblastoma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
HEC-73543 | HEC-73543 | Phase 3 Clinical | Hec Pharm Co Ltd | Leukemia, Myeloid, Acute | Details |
Crenolanib Besylate | CP-868596-26; IND-112201; CP-868596; ARO-002; ARO-002-26 | Phase 3 Clinical | Pfizer Inc | Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Glioma | Details |
HYML-122 | HYML-122; CHMFL-FLT3-122 | Phase 2 Clinical | Hefei Academy Of Physical Sciences, Chinese Academy Of Sciences, Hefei Cosource Pharmaceuticals | Leukemia, Myeloid, Acute | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
MRX-2843 | UNC-2371; UNC-2025; MRX-2843 | Phase 2 Clinical | University Of North Carolina At Chapel Hill | Leukemia; Solid tumours; Neoplasms; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lung Neoplasms; Leukemia, Myeloid, Acute; Neoplastic Processes; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Emavusertib | AU-4948; CA-4948 | Phase 2 Clinical | Aurigene | Anemia; Stomach Neoplasms; Esophageal Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Digestive System Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Pancreatic Ductal; Lymphoma, Non-Hodgkin; Gastrointestinal Neoplasms; Melanoma | Details |
Zotiraciclib | TG-02; SB-1317 | Phase 2 Clinical | Syncore Biotechnology Co Ltd | Glioblastoma; Neoplasms; Brain Neoplasms; Astrocytoma; Gliosarcoma; Glioma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular | Details |
NMS-03592088 | NMS-P088; NMS-03592088 | Phase 2 Clinical | Nerviano Medical Sciences Srl | Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
MAX-40279 | MAX-40279-001; Max-40279; MAX-40279-01; MAX-4 | Phase 2 Clinical | Maxinovel Pharmaceuticals Co Ltd | Solid tumours; Leukemia; Esophageal Neoplasms; Stomach Neoplasms; Idiopathic Pulmonary Fibrosis; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis | Details |
Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Fms-like tyrosine kinase 3 ligand (Celldex Therapeutics) | CDX-301 | Phase 2 Clinical | Amgen Inc | Sarcoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Osteosarcoma; Skin Melanoma; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Myelodysplastic Syndromes; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Leukemia, Myelogenous, Chronic | Details |
Tuspetinib | HM-43239 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
Flysyn | 4G8-SDIEM | Phase 2 Clinical | Synimmune Gmbh | Leukemia, Myeloid, Acute | Details |
Glesatinib | MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 | Phase 2 Clinical | Mirati Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
FF-10101 | FF-10101; FF-10101-01; FF-10101 succinate | Phase 2 Clinical | Fujifilm Corp | Leukemia, Myeloid, Acute | Details |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
Anti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine) | TAA05 | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
Flonoltinib maleate | Phase 2 Clinical | Chengdu Zenitar Biomedical Technology Co Ltd | Polycythemia Vera; Alopecia Areata; Myeloproliferative Disorders; Primary Myelofibrosis; Lymphohistiocytosis, Hemophagocytic; Thrombocythemia, Essential | Details | |
EP-0042 | EP-0042 | Phase 2 Clinical | Ellipses Pharma | Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
MEN-1703 | SEL-24-1; MEN-1703; SEL24/MEN1703; SEL24; SEL-24; SEL-24-B489 | Phase 2 Clinical | Ryvu Therapeutics Sa | Leukemia, Myeloid, Acute | Details |
FN-1501 | FN-1501; LT-171-861 | Phase 2 Clinical | China Pharmaceutical University, Shanghai Fosun Pharmaceutical Industrial Development Co Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular | Details |
Mivavotinib | TAK-659; CB-659 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd | Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
E-6201 | E-6201 | Phase 1 Clinical | Eisai Co Ltd | Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Psoriasis; Brain metastases; Leukemia, Myeloid, Acute; Melanoma | Details |
SENTI-202 | SENTI-202 | Phase 1 Clinical | Senti Biosciences Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
ETH-155008 | ETH-155008 | Phase 1 Clinical | Yunnan Shengke Pharmaceutical Co Ltd | Leukemia; Leukemia, Promyelocytic, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute | Details |
CLN-049 | CLN-049 | Phase 1 Clinical | University Of Tubingen, German Cancer Research Center (Dkfz) | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
Lomonitinib | Phase 1 Clinical | Eilean Therapeutics LLC | Details | ||
KME-0584 | KME-0584 | Phase 1 Clinical | National Center For Advancing Translational Sciences, Cincinnati Children'S Hospital Medical Center | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Lomonitinib | ZE46-0134; ZE-46-0134; ZE-460134 | Phase 1 Clinical | Eilean Therapeutics LLC | Leukemia, Promyelocytic, Acute; Leukemia, Myeloid, Acute | Details |
ETH-155036 | ETH-155036; ETH155036 | Phase 1 Clinical | Shengke Pharmaceutical (Jiangsu) Co Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
BMF-500 | BMF-500 | Phase 1 Clinical | Biomea Fusion Inc | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
PHI-101 | PHI-101; PHI-101-002; PHI-101-003 | Phase 1 Clinical | Pharos iBio Co Ltd | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute | Details |
LNK-01002 | LNK01002 | Phase 1 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Hematologic Neoplasms; Polycythemia Vera; Myeloproliferative Disorders; Primary Myelofibrosis; Leukemia, Myeloid, Acute | Details |
SKI-G-801 | G-801; SKI-G-801; G-749 Hydrochloride | Phase 1 Clinical | Oscotec Inc | Solid tumours; Leukemia, Myeloid, Acute | Details |
Luxeptinib | CG-806; CG-026806 | Phase 1 Clinical | Crystalgenomics Inc, Aptose | Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
This web search service is supported by Google Inc.